News and Announcements
First Two Patients in Clinical Trial for Canine Cancer Begin Treatment
- Published October 23, 2014 9:36AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ASX Release – Wednesday 22nd October 2014
PharmAust Limited (ASX:PAA & PAAO) is pleased to announce that it has now initiated its trial of PPL-1 in dogs for the treatment of canine cancers. Within the last week, two dogs have begun treatment with PPL-1 formulated in “soft-gel” capsules to determine the safety and efficacy of PPL-1 in various canine cancers.
Dr Angela Frim berger of the Animal Referral Hospital (ARH) in Homebuss, NSW and Principal Investigator in the trial said,” The palatability issues of PPL-1 in dogs have largely been resolved by reformulation of PPL-1 into a tasteless, soft gel capsule making administration to pets by their owners far more practicable. Following our call for accrual of canine patients, we are seeing good progress in patient recruitment.”
To view the full ASX release, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
